AZD1656

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Type 2 DiabetesType 2 Diabetes MellitusHypoglycemia

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

Spikevax

Moderna

Preclinical

212

AZD1656

AstraZeneca

Phase 2

13

COVID-19 Vaccine

Moderna

Preclinical

274

Stivarga

Bayer

Preclinical

15

Aimovig

Amgen

Preclinical

16

Aldactone

Pfizer

Preclinical

17

Nexavar

Bayer

Preclinical

18

Calciferol

Alnylam Pharmaceuticals

Preclinical

—9

Activella

Eli Lilly

Preclinical

—10

Tricor

JJagotec

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus11 trials

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Completed·AstraZeneca·Phase 2·NCT01020123·530 enrolled

Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

Completed·AstraZeneca·Phase 1·NCT01103609·16 enrolled

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

Completed·AstraZeneca·Phase 1·NCT01082120·28 enrolled

Show 8 more trials

Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus

Completed·AstraZeneca·Phase 1·NCT01095991·12 enrolled

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Completed·AstraZeneca·Phase 2·NCT00817778·27 enrolled

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Completed·AstraZeneca·Phase 2·NCT01152385·224 enrolled

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

Completed·AstraZeneca·Phase 1·NCT01103622·20 enrolled

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

Completed·AstraZeneca·Phase 1·NCT01069926·21 enrolled

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

Completed·AstraZeneca·Phase 1·NCT00916604·24 enrolled

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Completed·AstraZeneca·Phase 1·NCT00995787·75 enrolled

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

Completed·AstraZeneca·Phase 1·NCT01221519·20 enrolled

Type 2 Diabetes4 trials

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

Completed·AstraZeneca·Phase 2·NCT00856908·20 enrolled

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

Completed·AstraZeneca·Phase 1·NCT00747175·52 enrolled

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Completed·AstraZeneca·Phase 1·NCT00774553·70 enrolled

Show 1 more trial

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Completed·AstraZeneca·Phase 1·NCT00768105·24 enrolled

Oral3 trials

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Completed·AstraZeneca·Phase 1·NCT00741689·36 enrolled

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Completed·AstraZeneca·Phase 1·NCT01221545·24 enrolled

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Completed·AstraZeneca·Phase 1·NCT00726427·32 enrolled

Statin1 trial

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

Completed·AstraZeneca·Phase 1·NCT01096940·44 enrolled

Single Dose1 trial

To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

Completed·AstraZeneca·Phase 1·NCT01083212·19 enrolled

5 more indications

COVID-191 trial

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19

Completed·SSt George Street Capital·Phase 2·NCT04516759·170 enrolled

Immune Tolerance1 trial

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

Completed·QQueen Mary University of London·Phase 2·NCT05216172·26 enrolled

Hormonal Response1 trial

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

Completed·AstraZeneca·Phase 1·NCT00790153·12 enrolled

Hypoglycemia1 trial

To Evaluate the Response to Glucagon During Hypoglycemia

Completed·AstraZeneca·Phase 1·NCT00817271·8 enrolled

Unspecified2 trials

To Evaluate the Bioavailability of a Tablet of AZD1656

Completed·AstraZeneca·Phase 1·NCT00817505·11 enrolled

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Completed·AstraZeneca·Phase 1·NCT00819884·36 enrolled

Details

Drug Info

Related News